Answers are grounded in this paper and cite their sources.
Demonstrates improved antibody identification against high-prevalence antigens in transfusion medicine, indicating new immunohematology applications.
This study demonstrates that iPSC technology combined with gene editing can generate rare antigen-negative RBCs for immunohematology applications. Beyond MAM, this platform offers a strategy to create additional rare RBC phenotypes, advancing precision transfusion medicine and improving antibody identification against high-prevalence antigens.
No takes yet. Share an insight, caveat, or question.
Gunawardena et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: